STOCK TITAN

AYTU BioPharma (AYTU) Form 4 Filings

AYTU NASDAQ

Here are the Form 4 insider transactions from AYTU BioPharma, Inc. (AYTU) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow AYTU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AYTU filings page.

Rhea-AI Summary

Disbrow Joshua R. reported acquisition or exercise transactions in this Form 4 filing.

Joshua R. Disbrow, chief executive officer and director of Aytu Biopharma, received a grant of 30,000 shares of restricted common stock on July 28, 2026 at $0.00 per share. One-third vests on July 28, 2027, with the rest vesting in eight equal quarterly installments beginning October 28, 2027. After this award, he directly holds 237,203 common shares.

Rhea-AI Summary

PYSZCZYMUKA GREG reported acquisition or exercise transactions in this Form 4 filing.

Aytu BioPharma Chief Commercial Officer Greg Pyszczymuka received a grant of 20,000 shares of restricted common stock on July 28, 2026 at $0.0000 per share. One-third vests on July 28, 2027, with the remainder in eight quarterly installments from October 28, 2027. Following this award he directly holds 56,102 shares.

Rhea-AI Summary

Disbrow Jarrett reported acquisition or exercise transactions in this Form 4 filing.

Jarrett Disbrow, Chief Business Officer of AYTU Biopharma, reported a grant of 15,000 shares of common stock as restricted stock. The award increases his direct holdings to 76,568 shares and vests over time starting July 28, 2027 in quarterly installments.

Rhea-AI Summary

AYTU BioPharma’s Chief Financial Officer, Ryan J. Selhorn, received a grant of 25,000 shares of restricted common stock on July 28, 2026. One-third vests on July 28, 2027, with the remaining shares vesting in eight equal quarterly installments beginning October 28, 2027. Following this award, he directly holds 74,743 shares of common stock. The award is a grant/award acquisition rather than a market purchase and was not made under a Rule 10b5-1 trading plan.

Rhea-AI Summary

LIU VIVIAN H reported acquisition or exercise transactions in this Form 4 filing.

Aytu Biopharma director Vivian H. Liu received a grant of 10,000 shares of restricted common stock on July 28, 2026. The restricted stock vests on July 28, 2027. Following this grant, Liu directly holds 29,825 shares of Aytu Biopharma common stock.

Rhea-AI Summary

JAIN ABHINAV reported acquisition or exercise transactions in this Form 4 filing.

AYTU Biopharma reported that director Abhinav Jain received a grant of 10,000 shares of Common Stock as restricted stock on July 28, 2026, at a stated price of $0.0000 per share. These shares vest on July 28, 2027. After this award, Jain directly holds 29,500 shares of AYTU common stock.

Rhea-AI Summary

DOCKERY CARL reported acquisition or exercise transactions in this Form 4 filing.

Aytu BioPharma director Carl Dockery received a grant of 10,000 shares of restricted common stock on July 28, 2026. The shares vest on July 28, 2027, and his directly held position increased to 31,152 shares after this compensation-related award.

Rhea-AI Summary

Donofrio John Jr. reported acquisition or exercise transactions in this Form 4 filing.

Aytu BioPharma, Inc. director John Donofrio Jr. received a grant of 10,000 shares of restricted common stock on July 28, 2026. The award vests on July 28, 2027 and was priced at $0.00 per share, bringing his direct holdings to 23,762 shares.

Rhea-AI Summary

Officer grant and ownership change: The Chief Commercial Officer received a grant of 12,500 restricted shares of common stock that vest over time, increasing his beneficial ownership to 36,102 shares. The award was issued at a price of $0, indicating a stock-based compensation grant rather than a cash purchase. One-third of the restricted shares vest on 10/03/2026, with the remaining shares vesting in eight equal quarterly installments beginning 01/03/2027.

This transaction is a non-derivative, officer-level compensation event that aligns the officer's interests with shareholders through time-based vesting. The restricted nature of the shares means transfer or sale will be limited until vesting occurs.

Rhea-AI Summary

Reporting person: Jarrett Disbrow, Chief Business Officer and officer of AYTU BioPharma, Inc. (AYTU), reported equity grants on 10/03/2025. The filing shows two awards of restricted common stock issued at $0 per share: 19,606 shares granted as fully vested restricted stock in lieu of an annual cash bonus, and 12,500 shares granted as time‑based restricted stock.

The newly reported grants raise the reporting person’s total beneficial ownership to 61,568 shares. The time‑based award vests one‑third on 10/03/2026 and the remainder in eight equal quarterly installments beginning 01/03/2027

Rhea-AI Summary

AYTU Biopharma (AYTU) Chief Financial Officer Ryan J. Selhorn reported two grants of restricted common stock on 10/03/2025. He received 16,243 fully vested shares paid in lieu of cash for his annual bonus and an additional 17,500 restricted shares that vest over time: 1/3 on 10/03/2026 and the remainder in eight equal quarterly installments beginning 01/03/2027. The grants were reported with a $0 purchase price, and following these transactions Mr. Selhorn beneficially owned 49,743 shares in total after the awards. The filing is signed by Mr. Selhorn on 10/07/2025.

Rhea-AI Summary

Insider filing summary: The Form 4 shows that Joshua R. Disbrow, CEO and director of AYTU BioPharma (AYTU), received restricted common stock on 10/03/2025. He was granted 31,446 shares as fully vested restricted stock in lieu of his annual bonus and an additional 22,500 restricted shares that vest over time. After these grants his reported beneficial ownership rose to 207,203 shares.

The 22,500-share award vests 1/3 on 10/03/2026 with the remainder vesting in eight equal quarterly installments beginning 01/03/2027. Both grants had a reported price of $0, indicating they were awards rather than market purchases. The filing is signed by an attorney-in-fact on 10/07/2025.

Rhea-AI Summary

Vivian H. Liu, a Director of AYTU BIOPHARMA, INC (AYTU), reported a restricted stock grant of $0 price common stock on 10/03/2025. The filing shows 10,000 shares were granted and will vest on 10/03/2026. After the grant Ms. Liu beneficially owns 19,825 shares. The transaction is reported on a Form 4 and was signed by an attorney-in-fact on 10/07/2025. The award is described as restricted stock with a one-year vesting date; no cash purchase price was paid for the granted shares.

Rhea-AI Summary

Reporting person: Abhinav Jain, a director of AYTU BIOPHARMA, INC. (AYTU), reported a grant of 10,000 restricted shares on 10/03/2025. The restricted shares carry a vesting condition that they vest on 10/03/2026. The filing shows 19,500 shares beneficially owned by the reporting person after the transaction. The transaction is recorded as a non-derivative acquisition at a $0 price, consistent with a restricted stock grant. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/07/2025.

Rhea-AI Summary

Carl C. Dockery, a director of AYTU BioPharma, Inc. (AYTU), reported the grant of 10,000 restricted shares on 10/03/2025. The award carries an exercise price of $0 and is scheduled to vest on 10/03/2026. After this grant, Mr. Dockery beneficially owns 20,440 shares in total. The Form 4 was signed by an attorney-in-fact on 10/07/2025. The filing indicates these are non‑derivative restricted stock awards rather than open-market purchases, which affects the timing of when the shares become tradable.

Rhea-AI Summary

John A. Donofrio, Jr., a director of AYTU BioPharma, Inc. (AYTU), was granted 10,000 restricted shares on 10/03/2025. The grant carries a $0 per-share price and is described as restricted stock that vests on 10/03/2026.

Following the reported grant, the filing shows 13,762 shares beneficially owned by the reporting person. The Form 4 was signed on 10/07/2025 by an attorney-in-fact and includes a Power of Attorney exhibit.